GMP certification boost for Cobra Biologics

Published: 14-Feb-2014
Regulatory Pharmaceutical

Compliance certification now includes Quality Control testing


Contract manufacturing organisation Cobra Biologics has announced that its GMP Compliance Certification has been extended to include Quality Control (QC) testing and release of customers’ registered products for in-market supply.

Following an inspection at the company’s mammalian antibody and recombinant protein production plant in Södertälje, Sweden, the Läkemedelsverket (Medical Products Agency) said the facility complies with the principles and guidelines of Good Manufacturing Practice laid down in Commission Directive 2003/94/EC for Human Medicinal, and Investigational Medicinal, Products.

This enhanced certification for biological medicinal products encompasses the manufacturing of active substances by culture of mammalian cells, the storage of both mammalian and microbial cell banks, the release testing of protein for clinical trials, and now the quality control testing of registered products.

Peter Coleman, CEO Cobra Biologics said Quality Control testing of registered products is an important step for Cobra in becoming a recognised commercial supplier of antibodies and recombinant proteins.

'The future of the company is dependent on us securing commercial product manufacturing and the team has really put in every effort to secure the additional certification,' he said.

  • Companies:
  • Cobra Biologics
See more

You may also like

Manufacturing

How will COVID-19 accelerate vaccine development? Part II

Read more
Jim Sanford, Dr Sade Mokuolu and Peter Birch from Watson-Marlow Fluid Technology Group (WMFTG) continue their investigation and pose the question: what will we learn from this pandemic and how will it change the course of vaccine production?

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

How will COVID-19 accelerate vaccine development? Part II

Jim Sanford, Dr Sade Mokuolu and Peter Birch from Watson-Marlow Fluid Technology Group (WMFTG) continue their investigation and pose the question: what will we learn from this pandemic and how will it change the course of vaccine production?
Recruitment

CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies

Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Manufacturing

NEUWAY Pharma and Cobra Biologics collaborate to develop GMP-grade engineered protein capsules (EPCs) manufacturing process

Collaboration supports GLP toxicity studies and initiation of clinical development for the treatment of progressive multifocal leukoencephalopathy
Manufacturing

Cobra Biologics links up with CPI in £1.8m project to advance development of regenerative medicines

They will develop a scalable and flexible manufacturing process to produce, purify and characterise AAV vectors
Ingredients

Alligator Bioscience benefits from Cobra’s maxXpress platform

Cobra developed the cell line to express agonistic CD40 antibodies for an immuno-oncology application using its maxXpress platform
Manufacturing

Cobra and Tecrea win Innovate UK grant

To develop scalable Adeno Associated Virus (AAV) production bioprocess
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Interview: Focused and determined

Peter Coleman is CEO of Cobra Biologics, which provides clinical and commercial cGMP contract manufacturing of biologics and pharmaceuticals. He talks to Jane Ellis about the company’s history and where he wants to take it in the future
Subscribe now